Navigation Links
Researchers identify how a gene linked to both Alzheimer's disease and type 2 diabetes works
Date:7/18/2011

Researchers at Mount Sinai School of Medicine have identified how a gene for a protein that can cause Type 2 diabetes, also possibly kills nerve cells in the brain, thereby contributing to Alzheimer's disease.

The gene, called SorCS1, controls the generation of amyloid-beta (Abeta) in the brain. Abeta plays a key role in the development of Alzheimer's disease. The researchers previously linked SorCS1 to Alzheimer's disease and identified where the molecules lived in the cell, but not how they control Abeta. The new data were presented today at the Alzheimer's Association's Annual International Conference in Paris.

Sam Gandy, MD, PhD, the Mount Sinai Professor in Alzheimer's Disease Research, Professor of Neurology and Psychiatry, and Associate Director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine, led the research team with Rachel Lane, PhD, a postdoctoral researcher in Dr. Gandy's lab.

The researchers determined various "traffic patterns" in the cell for the amyloid precursor protein (APP) that makes Abeta and uncovered how much APP is converted into the toxic, and ultimately nerve-killing, Abeta. In some experiments Drs. Lane and Gandy altered the dose of the diabetes gene, SorCS1, and evaluated how that changed the "traffic pattern" that APP used to move around the cell and generate Abeta. In other experiments, Dr. Lane made small changes in the SorCS1 gene's and again saw dramatic changes in the "traffic pattern" of APP around the cell.

These data suggest that SorCS1 controls the movement of APP within the cell between areas where Abeta is readily made to areas where Abeta is not so easily made. In turn, the "traffic pattern" of influences the amount of Abeta being made by cells. The implication is that people with deficiencies in SorCS1 are at higher risk of developing Alzheimer's disease because their APP spends too much time in the region of the cell where APP is broken down to make the toxic Abeta.

"The great thing about studying SorCS1," said Dr. Gandy, "is that we already have entirely new ideas about how to treat both Alzheimer's disease and type 2 diabetes. Our hunch is that SorCS1 also controls how the insulin receptor moves around the cell, but we have not yet proven that," he said. "With both diseases reaching epidemic proportions, this discovery is encouraging news that brings us one step closer to developing treatments."


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. NYU researchers develop compound to block signaling of cancer-causing protein
2. Mayo researchers: Genetic mutation linked to Parkinsons disease
3. Researchers Closer to Developing Universal Meningitis B Vaccine
4. Novel Virus Jumped From Monkeys to Humans, Researchers Find
5. Dentists can identify people with undiagnosed diabetes, Columbia researchers show
6. UAB researchers present a study on the psychological adaptation of adopted children
7. Researchers identify key role of microRNAs in melanoma metastasis
8. A change of heart: Penn researchers reprogram brain cells to become heart cells
9. Researchers identify early biomarker for future atopy in asymptomatic children
10. Berkeley Lab researchers apply NMR/MRI to microfluidic chromatography
11. Leeds researchers test benefit of fish oil in bowel cancer spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ... from offices headquartered in Jefferson County, is announcing the launch of a charity ... , The number of homeless women and children in Birmingham has grown steadily ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a ... clients in and around the Hancock County area, is announcing the launch of a ... Pantry. , The Hancock County Food Pantry has worked for more than 30 years ...
(Date:12/7/2016)... ... 2016 , ... DrugDev again demonstrated its dedication to reducing the ... early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... of the Atlantic with a mechanism to comply with EU data protection requirements when ...
(Date:12/7/2016)... ... 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for ... is a multi-function, sealed, LED luminaire that meets the needs of everyone in the ... needed. , A 2’ x 4’ model features four modes: reading, ambient, ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry ... Control through a new partnership with Splashtop Inc. This remote control for Android ... to help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016  Hanson Research, an innovative leader in ... diffusion testing instruments for the pharmaceutical industry, announced ... Inc. ("Teledyne"). The move is designed to deepen ... instruments, as well as expand resources for further ... and services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
(Date:12/8/2016)... , Dec. 8, 2016  Haemonetics Corporation (NYSE: ... (Donor Management System), an innovative software suite designed to help ... The launch of NextGen DMS 4 improves core features ... the cost per liter of plasma collected, enhancing quality and ... center operations. ...
(Date:12/8/2016)...   Mederi Therapeutics Inc . has announced regulatory approval by CFDA and product ... chronic gastroesophageal reflux disease (GERD). Continue Reading ... ... Congress of Digestive Endoscopy, by Professor Jun Liu, Director of Endoscopy at Wuhan Union ... "We are very pleased that Mederi products are ...
Breaking Medicine Technology: